DEXAMETHASONE SODIUM PHOSPHATE | A084916 | FRESENIUS KABI USA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from GeneYork Pharmaceuticals Group LLC FDA-2018-P-0614 · 4 docket documents GeneYork Pharmaceuticals, LLC filed this citizen petition on February 7, 2018 requesting that the FDA designate ANDA 084916 owned by Fresenius Kabi USA, Inc. as an alternate reference standard for the discontinued referenced listed drug HEXADROL (Dexamethasone Sodium Phosphate Injection) originally | 505(q) | 2018-02-08 | Granted | GeneYork Pharmaceuticals Group LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.6742
per ml
Lowest NADAC/Unit
$0.2381
per ml
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 63323016516DEXAMETHASONE 4 MG/ML VIAL | $0.6742 | ML | Generic | — | 2026-06-17 |
| 63323016501DEXAMETHASONE 4 MG/ML VIAL | $0.6742 | ML | Generic | — | 2026-06-17 |
| 81565020202DEXAMETHASONE 4 MG/ML VIAL | $0.6742 | ML | Generic | — | 2026-06-17 |
| 63323016530DEXAMETHASONE 120 MG/30 ML VL | $0.6112 | ML | Generic | — | 2026-06-17 |
| 63323016526DEXAMETHASONE 20 MG/5 ML VIAL | $0.2381 | ML | Generic | — | 2026-03-18 |
| 63323016505DEXAMETHASONE 20 MG/5 ML VIAL | $0.2381 | ML | Generic | — | 2026-03-18 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.